Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vistin Pharma ASALTS:0RAM +0.99%75 Shiller PE Ratio is 25.50 as of Jul. 21, 2026, which is 16% below its 10-year median of 30.50. GuruFocus rates LTS:0RAM with a GF Score™ of 75/100 and a GF Value™ of kr25.76 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 538 Drug Manufacturers companies, Vistin Pharma ASA ranks worse than 51.67% on this metric.
The historical rank and industry rank for Vistin Pharma ASA's Shiller PE Ratio or its related term are showing as below:
LTS:0RAM'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 25.5 Med: 30.5 Max: 41.03
Current: 25.78
During the past years, Vistin Pharma ASA's highest Shiller PE Ratio was 41.03. The lowest was 25.50. And the median was 30.50.
LTS:0RAM's Shiller PE Ratio is ranked worse than 51.67% of 538
companies
in the Drug Manufacturers industry
Industry Median: 24.885
vs LTS:0RAM: 25.78
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Vistin Pharma ASA's adjusted earnings per share data for the three months ended in Mar. 2026 was kr0.480. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is kr0.80 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Vistin Pharma ASA (LTS:0RAM) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Vistin Pharma ASA Shiller PE Ratio Related Terms
Vistin Pharma ASA Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for Vistin Pharma ASA's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RAM vs ZTS, UTHR, VTRS: Shiller PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA Shiller PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistin Pharma ASA's E10 for the quarter that ended in Mar. 2026 is calculated as:
For example, Vistin Pharma ASA's adjusted earnings per share data for the three months ended in Mar. 2026 was:
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Vistin Pharma ASA (LTS:0RAM) has a Shiller PE Ratio of 25.50 as of Jul. 21, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Vistin Pharma ASA and its competitors. This is 16% below median its historical median of 30.50. Over the past decade, Vistin Pharma ASA's Shiller PE Ratio has ranged from 25.50 to 41.03. According to the industry distribution chart, Vistin Pharma ASA ranks #278 out of 538 companies in the Drug Manufacturers industry, placing it in the top 51.7%.
Is Vistin Pharma ASA's Shiller PE Ratio too high?
Vistin Pharma ASA's current Shiller PE Ratio of 25.50 is 16% below median its 10-year median of 30.50. Over the past 10 years, this metric has ranged from a low of 25.50 to a high of 41.03. The Drug Manufacturers industry median Shiller PE Ratio is 24.89. Vistin Pharma ASA's value of 25.50 is 2.5% above this industry median. Based on the distribution chart, Vistin Pharma ASA ranks #278 out of 538 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vistin Pharma ASA has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Shiller PE Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #278 out of 538 companies for Shiller PE Ratio. This places Vistin Pharma ASA in the lower half of its industry. The industry median Shiller PE Ratio is 24.89. Vistin Pharma ASA's value of 25.50 is 2.5% above this benchmark. Historically, Vistin Pharma ASA's own Shiller PE Ratio has ranged from 25.50 to 41.03 over the past decade. While the company's 10-year median is 30.50 vs. the industry median of 24.89, Vistin Pharma ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Drug Manufacturers company?
The median Shiller PE Ratio among Drug Manufacturers companies is 24.89, based on 538 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistin Pharma ASA's current Shiller PE Ratio of 25.50 is 2.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median Shiller PE Ratio is 24.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current Shiller PE Ratio is 25.50, which is 16% below median its own 10-year median of 30.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.76, compared to a current price of kr20.40 — trading 20.8% below its estimated fair value. The current Shiller PE Ratio is 25.50, which is 16% below median its 10-year median of 30.50 and 2.5% above the Drug Manufacturers industry median of 24.89. Vistin Pharma ASA's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Shiller PE Ratio is 25.50 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr20.40 is trading 20.8% below its estimated GF Value™ of kr25.76.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for LTS:0RAM:
Shiller PE Ratio: 25.50 (16% below median its 10-year median of 30.50)
GF Value™: kr25.76 vs. price of kr20.40 (20.8% below fair value)
Industry Position: 2.5% above the Drug Manufacturers median (#278 of 538)
No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
75GF Score
Get the complete analysis for LTS:0RAM
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAM has been successfully added to your 
